Rianna Modi

Oct 8, 2024 | lexology.com | Alice Valder Curran |Ken Choe |Melissa Bianchi |Joy Sturm |Allison Pugsley |Kathleen Peterson | +6 more

On October 2, 2024, the Centers for Medicare & Medicaid Services (CMS) issued final guidance for initial price applicability year (IPAY) 2027 of the Drug Price Negotiation Program established by the Inflation Reduction Act (IRA) (“Final Guidance”). The Final Guidance largely represents a continuation of CMS’s IPAY 2026 approach.

Sep 23, 2024 | lexology.com | Alice Valder Curran |Ken Choe |Kathleen Peterson |Samantha Marshall |Mahmud Brifkani |Rianna Modi | +4 more

On September 20, 2024, the Centers for Medicare & Medicaid Services (CMS) issued a final rule entitled: Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program.

Aug 14, 2024 | jdsupra.com | James Huang |Stuart Langbein |Rianna Modi

August 14, 2024 James Huang, Stuart Langbein, Rianna Modi, Beth Roberts, Victoria Wallace Hogan Lovells + Follow x Following x Following - Unfollow Contact To embed, copy and paste the code into your website or blog: On August 7, 2024, the Centers for Medicare & Medicaid Services (CMS) released a Final Notice for Transitional Coverage for Emerging Technologies (TCET) (Final Notice).

Aug 14, 2024 | lexology.com | Stuart Langbein |Beth Roberts |James Huang |Victoria Wallace |Rianna Modi

On August 7, 2024, the Centers for Medicare & Medicaid Services (CMS) released a Final Notice for Transitional Coverage for Emerging Technologies (TCET) (Final Notice). The long-anticipated Final Notice on the TCET pathway finalizes a new mechanism to provide Medicare patients with more timely and predictable access to certain Food and Drug Administration (FDA) designated Breakthrough devices.

May 6, 2024 | lexology.com | Alice Valder Curran |Ken Choe |Susan Cook |Kathleen Peterson |Samantha Marshall |Lindsey Johnson | +3 more

On May 3, 2023, the Centers for Medicare & Medicaid Services (CMS) issued draft guidance for initial price applicability year (IPAY) 2027 of the Drug Price Negotiation Program established by the IRA. Notwithstanding the agency’s oft-stated claim in litigation that its guidance for IPAY 2027 may differ from that for IPAY 2026, the draft guidance largely represents a continuation of CMS’s IPAY 2026 approach.